PALI
What one share of Palisade Bio holds
Biological Products, (No Diagnostic Substances)
We are a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral phosphodiesterase-4 (“PDE4”) inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon. Our lead clinical product candidate, PALI-2108, is being developed as a treatment for patients living with inflammatory bowel disease (“IBD”), including ulcerative colitis (“UC”) and Crohn’s disease (“CD”).
Palisade Bio’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.00 |
|---|---|
| Profit | −$0.20 |
| Cash and investments | $0.72 |
| Book value | $0.70 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2021 | — | −$2,546 | $0.00 | −$1,185 | — | $387.93 |
| 2022 | $0.00 | −$247.89 | $0.17 | −$227.82 | — | — |
| 2023 | $0.55 | −$27.01 | $0.01 | −$24.42 | — | $18.30 |
| 2024 | $0.00 | −$10.19 | $0.00 | −$8.61 | — | $2.71 |
| 2025 | $0.00 | −$0.30 | — | −$0.19 | — | $0.81 |